Suggested remit: To appraise the clinical and cost effectiveness of standardised quality house dust mite sublingual immunotherapy (SQ HDM SLIT) within its marketing authorisation for treating allergic rhinitis and/or allergic asthma associated with allergic rhinitis caused by house dust mites.
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3961

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
15 March 2022 (10:00) Scoping workshop
20 January 2022 - 17 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual